Table 4.

The therapies in phase 3 clinical trials targeting synaptic compartments are small molecules

Name	Role	Clinical trial registration
AGB101	Binding to the synaptic vesicle (SV) protein SV2A	NCT03486938
Mastinib	Inhibitor of tyrosine kinase, Lyn and Fyn kinase	NCT05564169
Simufilam	Binds to filamin to stabilize actin	NCT05026177

AGB101: AgeneBio, Inc.; SV2A: Synaptic vesicle glycoprotein 2A. Other therapeutic targets may still have benefits to synapses by targeting pathways required for synaptic function.